RU2798339C1 - Agent for treatment of acute mastitis in cattle - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: invention relates to an agent for the treatment of acute mastitis in cattle containing enrofloxacin, carbacholin and aloe extract in the following ratio, wt.%: enrofloxacin — 3.59; carbacholin — 0.36; aloe extract — 35.93; magnesium stearate — 2.63; vaseline oil — 57.49.

EFFECT: above agent provides treatment of acute mastitis in cattle, effect on all parts of the pathological process, combining antibacterial, anti-inflammatory, contractile and restorative effects, high therapeutic efficacy.

1 cl, 2 tbl, 3 ex

Description

The invention relates to the field of agriculture, in particular to veterinary medicine, and can be used to treat mastitis in cattle.

Mastitis in cows is widespread and causes great economic damage to livestock. Animals can get sick at any time of the year, at different periods of lactation and during the dry period. The problem of combating microorganisms that cause infectious diseases in humans and animals is very relevant, despite the fairly large selection of biocidal preparations.

Currently, several thousand chemical compounds are known to have biocidal properties, but only hundreds of them are used in practice for safety reasons. Every year, dozens of biocidal preparations are discontinued due to their low antimicrobial activity or high toxicity. In addition to the natural resistance of some microorganisms to biocidal preparations, microorganisms quickly adapt to adverse factors, including the effects of antimicrobial agents. Given this, as well as the increasing requirements for environmental safety of drugs, their toxicity and allergenicity, there is a constant need to search for fundamentally new environmentally friendly biocidal drugs.

The most relevant directions in the creation of new biocidal agents are not so much an increase in their antimicrobial activity (since, as a rule, their toxicity increases), but an increase in the duration of their antimicrobial action after surface treatment, a decrease in toxicity, allergenicity and environmental safety. Of great importance is also a wide range of biocidal action of drugs against pathogenic microflora, acceptable physico-chemical, hygienic and consumer properties.

Known drug for the treatment of prevention of mastitis in cattle, including antibiotic - ristomycin, lanomine and vaseline oil (US Pat. RF No. 2135166, 1999). However, the use of a preparation containing an antibiotic has a number of disadvantages: dysbacteriosis, prolonged release of antimicrobial substances with milk, and therefore milk is unsuitable for food purposes.

The study revealed a close analogue - Trade name of the drug: Mastijet Forte (Mastijet® Forte) (organization-developer: Intervet International B.V., the Netherlands). Dosage form: suspension for intracisternal administration, actively used in obstetrics and gynecology. Mastiet Forte in 1 dosing syringe contains as active ingredients: 200 mg of tetracycline (in the form of hydrochloride), 250 mg of neomycin (in the form of sulfate), 2000 IU of bacitracin and 10 mg of prednisolone, as excipients -368 mg of magnesium stearate and up to 8 g of vaseline oil. In appearance, the drug is a yellowish oily suspension.

The disadvantages of this drug are: the absence of an anti-inflammatory effect, a long therapeutic course involving the use of additional drugs, the content of high doses of antibiotics that have side effects, and the presence of inhibitory substances.

The objective of the claimed technical solution is to develop a new drug for the treatment of acute mastitis in cattle, acting on all parts of the pathological process, combining antibacterial, anti-inflammatory, contractile and restorative effects, with high therapeutic efficacy.

The problem is solved by using a pharmaceutical agent, including enrofloxacin, carbachol, aloe extract, and magnesium stearate and vaseline oil as excipients.

Enrofloxacin is an antibiotic from the group of fluoroquinolones. It has a wide spectrum of antibacterial and antimycoplasmal action. Therapeutic concentration is maintained for 24 hours after administration of the drug. Enrofloxacin penetrates into most organs and tissues of the body. It is excreted mainly unchanged and partially as a metabolite (ciprofloxacin) with urine and faeces.

Carbacholin increases the tone and intensifies contractions of the muscles of the uterus, stomach and intestines, digestive, bronchial, sweat, salivary and lacrimal glands, dilates peripheral vessels, slows down the heart rate, constricts the pupil, lowers intraocular pressure.

Aloe extract is a herbal remedy. Aloe juice, thanks to its bitter taste, enzymes and vitamins, stimulates the appetite and enhances the secretion of the digestive glands. Anthraglycoside aloin, free anthraquinones emodin and chrysophanol, resinous substances irritate the colon chemoreceptors, providing a laxative effect. Aloe has an anti-inflammatory effect, enhances the processes of regeneration of the mucous membranes and skin.

The composition is presented in the form of a dosage form (suspension) containing active substances - enrofloxacin, carbacholin, aloe extract and excipients - magnesium stearate and vaseline oil in the following ratio, wt. %: enrofloxacin -3.59; carbacholin - 0.36; aloe extract - 35.93; magnesium stearate - 2.63; vaseline oil - 57.49.

A new drug is prepared as follows: magnesium stearate and vaseline oil are weighed and mixed, then the required amount of carbachol is added and mixed. Separately, enrofloxacin, aloe extract are weighed and mixed. The two compositions are then combined and mixed until a suspension is obtained.

The proposed tool is an oily suspension of yellowish-green color with a pronounced smell of aloe.

Before the introduction, the udder is sanitized. The suspension is injected into each nipple intracisternally at a dose of one dosing syringe in a volume of 8 ml with an interval of 24 hours until recovery.

The claimed agent has a pronounced therapeutic effect in the treatment of acute mastitis in cattle, superior to the drug "Mastiet-forte" in terms of therapeutic efficacy.

Example 1

Calculation of the optimal composition of the product.

The ratio of active components in the proposed agent was determined taking into account the instructions for their use in three compositions at a ratio of components, wt. %:

Composition 1. Enrofloxacin - 3.59; carbacholin - 0.36; aloe extract - 35.93; magnesium stearate - 2.63, vaseline oil - 57.49.

Composition 2. Enrofloxacin - 7.18; carbacholin - 0.72; aloe extract - 35.93; magnesium stearate - 2.63, vaseline oil - 53.54.

Composition 3. Enrofloxacin - 1.795; carbacholin - 0.18; aloe extract - 17.965; magnesium stearate - 5.26, vaseline oil - 74.8.

To determine the optimal ratio of components in the proposed tool, cows were selected at the age of 3-4 years of the Holstein breed with signs of acute mastitis. Of these, according to the principle of pairs of analogues, 3 groups of 10 goals each were formed. Cows of the first group were injected with the agent in composition 1, the second - in composition 2, the third - in composition 3, intracisternally, at a dose of one syringe dispenser in a volume of 8 ml with an interval of 24 hours until recovery.

The results of the experiments are presented in table 1.

Improvement was noted in animals of the first and second groups on the fourth day, in cows of the third group, improvement occurred on days 4-5. In experimental animals, there was a decrease in inflammatory edema, the amount of catarrhal-purulent exudate. Recovery occurred in cows of group II and group I on average 1 day after the start of treatment earlier than cows of group III. Thus, the use of a new drug in composition 1 for the treatment of cows with acute mastitis contributed to their rapid recovery and had a positive effect on productive indicators.

Example 2

The timing of the release of a new drug with milk in an experimental group of cows with a number of 20 heads was controlled by determining the residual amounts of inhibitory substances by a method based on the reduction of methylene blue in milk with microorganisms of the species Streptococcus thermopiles from 1 to 3 days after the last intracisternal administration of the drug at a dose of one syringe - dispenser in a volume of 8 ml.

10 ml of test milk, 1 ml of methylene blue and 3-4 drops of thermophilic streptococcus were poured into a test tube, 10 ml of antibiotic-free milk, 1 ml of methylene blue and 3-4 drops of thermophilic streptococcus were poured into a control tube. The contents of the tubes were stirred and placed for 5.5 hours in a water bath at a temperature of 38 to 40°C.

The reaction was taken into account after 1 day, two days and 3 days after the end of the therapeutic course.

In the presence of an antibiotic, the milk would have a blue color. Discoloration of methylene blue was found in all samples, which indicated the absence of an antibiotic in milk.

Example 3

Production approbation of the use of a new drug for the treatment of cows with signs of acute mastitis was carried out in the SPK "RODINA" and the SPK "Kolos" of the Matveevo-Kurgan district of the Rostov region. These farms are free from contagious, including especially dangerous, animal diseases.

The production experience included Holstein cows with acute purulent-catarrhal mastitis, which in each of the farms, according to the principle of pairs of analogues, were divided into experimental and control groups of 20 cows each. The cows of the experimental groups were treated by introducing a new drug intracisternally at a dose of one syringe dispenser in a volume of 8 ml with an interval of 24 hours until recovery.

The cows of the second group were treated by intracisternal administration of "Mastiet Forte" at a dose of one syringe dispenser with an interval of 12 hours until recovery.

The animals were observed during the treatment period, taking into account the dynamics of the pathological process, the timing of recovery.

The results of industrial testing for the treatment of cows with mastitis are presented in table 2.

Both methods of treating cows with acute purulent-catarrhal mastitis were effective. However, in the experimental groups, the therapeutic course was on average shorter than in the control groups by 1-1.5 days. The dynamics of the pathological process in the groups also differed. In the experimental groups, the first signs of improvement occurred on the 3rd - 4th day of treatment, and in the control group a little later - on the 4th - 6th day.

Thus, the production approbation of a new drug with a therapeutic purpose in relation to acute mastitis in cows confirmed its high efficiency.

Claims (1)

An agent for the treatment of acute mastitis in cattle, containing active substances and excipients - magnesium stearate and vaseline oil, characterized in that enrofloxacin, carbacholin and aloe extract are used as active substances in the following ratio of components, wt.%: enrofloxacin - 3, 59; carbacholin - 0.36; aloe extract - 35.93; magnesium stearate - 2.63; vaseline oil - 57.49.